{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:22:14Z","timestamp":1789824134237,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":2562,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1038\/ki.2008.512","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T13:38:12Z","timestamp":1227706692000},"page":"S19-S23","source":"Crossref","is-referenced-by-count":54,"special_numbering":"S111","title":["Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide"],"prefix":"10.1016","volume":"74","author":[{"given":"Bego\u00f1a","family":"L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Hermida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Laviades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2008.512_bb0010","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000063551","article-title":"Cardiovascular changes in renal failure","volume":"20","author":"Tyralla","year":"2002","journal-title":"Blood Purif"},{"issue":"Suppl. 84","key":"10.1038\/ki.2008.512_bb0015","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1046\/j.1523-1755.63.s84.1.x","article-title":"Morphology of the heart and arteries in renal failure","volume":"63","author":"Tyralla","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.512_bb0020","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1524-6175.2007.06626.x","article-title":"Mechanisms of cardiac fibrosis in hypertension","volume":"9","author":"D\u00edez","year":"2007","journal-title":"J Clin Hypertens"},{"key":"10.1038\/ki.2008.512_bb0025","first-page":"135","article-title":"Hypertensive heart disease in the patient with chronic kidney disease","volume":"28","author":"D\u00edez","year":"2008","journal-title":"Nefrolog\u00eda"},{"key":"10.1038\/ki.2008.512_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cardiores.2005.05.014","article-title":"Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch","volume":"68","author":"Pemberton","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1038\/ki.2008.512_bb0035","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/bbrc.1999.1535","article-title":"Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes","volume":"264","author":"Hishinuma","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/ki.2008.512_bb0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0272-6386(96)90357-1","article-title":"Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention","volume":"27","author":"Levin","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.512_bb0045","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.512_bb0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ccl.2005.04.002","article-title":"Congestive heart failure in chronic kidney disease: disease specific mechanisms of systolic and diastolic heart failure and management","volume":"23","author":"Curtis","year":"2005","journal-title":"Cardiol Clin"},{"key":"10.1038\/ki.2008.512_bb0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000104092","article-title":"Diastolic function in several stages of chronic kidney disease in patients with autosomal dominant polycystic kidney disease: a tissue Doppler imaging study","volume":"30","author":"de Almeida","year":"2007","journal-title":"Kidney Blood Press Res"},{"key":"10.1038\/ki.2008.512_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ncpcardio0158","article-title":"Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease","volume":"2","author":"D\u00edez","year":"2005","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1038\/ki.2008.512_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/clc.4960270412","article-title":"Dynamic assessment of myocardial involvement in patients with end-stage renal disease by ultrasonic tissue characterization and serum markers of collagen metabolism","volume":"27","author":"Fatema","year":"2004","journal-title":"Clin Cardiol"},{"key":"10.1038\/ki.2008.512_bb0070","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1291\/hypres.28.787","article-title":"Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers","volume":"28","author":"Shibasaki","year":"2005","journal-title":"Hypertens Res"},{"key":"10.1038\/ki.2008.512_bb0075","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/sj.ki.5000249","article-title":"Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging","volume":"69","author":"Mark","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.512_bb0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/01.HYP.36.4.517","article-title":"Transforming growth factor beta in hypertensives with cardiorenal damage","volume":"36","author":"Laviades","year":"2000","journal-title":"Hypertension"},{"key":"10.1038\/ki.2008.512_bb0085","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000017264.66561.3D","article-title":"Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients","volume":"105","author":"D\u00edez","year":"2002","journal-title":"Circulation"},{"key":"10.1038\/ki.2008.512_bb0090","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.107.716886","article-title":"Role of left ventricular stiffness in heart failure with normal ejection fraction","volume":"117","author":"Westermann","year":"2008","journal-title":"Circulation"},{"key":"10.1038\/ki.2008.512_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/HYPERTENSIONAHA.108.112334","article-title":"Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease","volume":"52","author":"Wang","year":"2008","journal-title":"Hypertension"},{"key":"10.1038\/ki.2008.512_bb0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.amjcard.2006.08.042","article-title":"Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study","volume":"99","author":"Ahmed","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1038\/ki.2008.512_bb0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.ajkd.2006.10.021","article-title":"Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure","volume":"49","author":"Afshinnia","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.512_bb0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.crd.0000148162.88296.9f","article-title":"Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency","volume":"14","author":"Das","year":"2006","journal-title":"Cardiol Rev"},{"key":"10.1038\/ki.2008.512_bb0115","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1046\/j.1523-1755.2003.00273.x","article-title":"Role of excess volume in the pathophysiology of hypertension in chronic kidney disease","volume":"64","author":"Vasavada","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.512_bb0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003495-199549010-00009","article-title":"Torasemide: an update of its pharmacological properties and therapeutic efficacy","volume":"49","author":"Dunn","year":"1995","journal-title":"Drugs"},{"key":"10.1038\/ki.2008.512_bb0125","series-title":"The Kidney","first-page":"1646","article-title":"Diuretics","author":"Ellison","year":"2008"},{"key":"10.1038\/ki.2008.512_bb0130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1388-9842(02)00122-8","article-title":"Torasemide in chronic heart failure: results of the Toric Study","volume":"4","author":"Cos\u00edn","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1038\/ki.2008.512_bb0135","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1253\/circj.67.384","article-title":"Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure","volume":"67","author":"Yamato","year":"2003","journal-title":"Circ J"},{"issue":"Suppl","key":"10.1038\/ki.2008.512_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00541464","article-title":"Torasemide, a new potent diuretic: double-blind comparison with furosemide","volume":"31","author":"Broekhuysen","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1038\/ki.2008.512_bb0145","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(01)00903-2","article-title":"Open-label randomized trial of torasemide compared with furosemide therapy for patients with heart failure","volume":"111","author":"Murray","year":"2001","journal-title":"Am J Med"},{"key":"10.1038\/ki.2008.512_bb0150","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2003.12.052","article-title":"Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure","volume":"43","author":"L\u00f3pez","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2008.512_bb0155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2007.11.034","article-title":"Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy","volume":"581","author":"Veeraveedu","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1038\/ki.2008.512_bb0160","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bcp.2007.09.026","article-title":"Comparative effects of torasemide and furosemide in rats with heart failure","volume":"75","author":"Veeraveedu","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1038\/ki.2008.512_bb0165","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jacc.2007.04.080","article-title":"Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure","volume":"50","author":"L\u00f3pez","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2008.512_bb0170","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/jcb.10646","article-title":"Expression of procollagen C-proteinase enhancer in cultured rat heart fibroblasts: evidence for co-regulation with type I collagen","volume":"90","author":"Shalitin","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1038\/ki.2008.512_bb0175","doi-asserted-by":"crossref","first-page":"19059","DOI":"10.1074\/jbc.272.30.19059","article-title":"Transforming growth factor-beta regulation of bone morphogenetic protein-1\/procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes","volume":"272","author":"Lee","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2008.512_bb0180","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.jacc.2004.09.009","article-title":"Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure","volume":"44","author":"Tsutamoto","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2008.512_bb0185","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0960-894X(01)00384-5","article-title":"Amino acid derived sulphonamide hydroxamates as inhibitors of procollagen C-proteinase: solid-phase synthesis of ornithine analogues","volume":"11","author":"Dankwardt","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1038\/ki.2008.512_bb0190","first-page":"103","article-title":"Chemistry of torasemide. Molecular and crystal structure of new polymorph N","volume":"74","author":"Danilowski","year":"2001","journal-title":"Croat Chem Acta"},{"issue":"Suppl 1","key":"10.1038\/ki.2008.512_bb0195","first-page":"48","article-title":"Single-dose, randomized, cross-over bioavailability pilot clinical trial of torasemide immediate release compared to a new prolonged release formulation of torasemide","volume":"99","author":"Gropper","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"Suppl 1","key":"10.1038\/ki.2008.512_bb0200","first-page":"48","article-title":"Single and repeated-dose, randomized, cross-over, bioavailability clinical trial of torasemide immediate release compared to a new prolonged release formulation of torasemide","volume":"99","author":"Gropper","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1038\/ki.2008.512_bb0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1527-3466.2008.00046.x","article-title":"Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release","volume":"26","author":"Roca-Cusachs","year":"2008","journal-title":"Cardiovasc Ther"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815532286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815532286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T04:51:20Z","timestamp":1545627080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815532286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":40,"alternative-id":["S0085253815532286"],"URL":"https:\/\/doi.org\/10.1038\/ki.2008.512","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}